Company Information
CIN
Status
Date of Incorporation
11 August 1988
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
27 September 2023
Paid Up Capital
327,454,980
Authorised Capital
500,000,000
Directors
Pravin Dilip Pawar
Director/Designated Partner
about 2 years ago
about 2 years ago
Binod Chandra Maharana
Director/Designated Partner
about 2 years ago
about 2 years ago
Mohan Kumar Rayana
Director/Designated Partner
about 2 years ago
about 2 years ago
Pallavi Prakash Shedge
Director/Designated Partner
over 3 years ago
over 3 years ago
Anupama Vaidya
Director/Designated Partner
over 3 years ago
over 3 years ago
Vinod Rang Lal Verma
Cfo
over 9 years ago
over 9 years ago
Anita Belani
Director
about 10 years ago
about 10 years ago
Jitendra Jayantilal Gandhi
Company Secretary
over 10 years ago
over 10 years ago
Ashokkumar Narayan Shinkar
Director
almost 15 years ago
almost 15 years ago
Chandran Krishnamoorthy
Whole Time Director
over 15 years ago
over 15 years ago
Narinder Kumar Puri
Director
over 20 years ago
over 20 years ago
Past Directors
Manisha Meenesh Juvekar
Additional Director
almost 5 years ago
almost 5 years ago
Poonam Arya Bharti
Additional Director
over 7 years ago
over 7 years ago
Divakar Kaza
Director
about 8 years ago
about 8 years ago
Sanjay Kumar Bhattacharyya
Director
about 12 years ago
about 12 years ago
Manish Krishnarao Joshi
Nominee Director
over 12 years ago
over 12 years ago
Koduru Rama Narasinha Moorthy
Whole Time Director
over 20 years ago
over 20 years ago
Sudip Sudhir Chandra Bhattacharyya
Nominee Director
over 20 years ago
over 20 years ago
Arun Laxman Bongirwar
Director
over 20 years ago
over 20 years ago
Pyarelal Tiwari
Director
over 20 years ago
over 20 years ago
Patents
The present application relates to novel amine oxazolidinones derivatives of compound formula (I), and process for preparation thereof. Further relates to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in pa...
The present invention discloses the novel process for
preparation of Apixaban intermediate formula (D), Intermediate
formula (E) and preparation of Apixaban from theses
intermediates.
The present invention provides a process for the preparation of Anagliptin or its pharmaceutically acceptable salts thereof. The present invention further provides the novel intermediates for the preparation of Anagliptin and process for the preparation thereof.
The present invention discloses an improved process for preparation of crystalline salt of 1-(9H-carbazole-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl] amino]-propan-2-ol, phosphate monohydrate (carvedilol phosphate monohydrate) of formula (I).
The present invention discloses novel synthetic processes involving Heck"s coupling reaction of 2-sinstituted thiophene with Heck alkene acceptor such as suitably substituted amide or N-substituted allyl amine or N-methyl acrylamide which is optionally hydrated or acetylated and further subjected to Michael addition...
The present invention relates to the process for preparation, isolation and purification of Cilastatin acid of formula -I or its pharmaceutically accepted salt by treating 7-chloro-2-[[(1S)-2,2'-di-methylcyclopropane] carboxamide]-2-heptanoic acid of formula-Ill with L-cysteine hydrochloride in presence of base in a...
The present invention discloses an improved process for preparation of Sodium-4-carboxy-3-hydroxy-5-mercaptoisothiazole, ISONA compound of formula 1. The process involves the conversion of propanedinitrile to. disodium 2,2 -dicyanoethene-1,1-bis(thiolate), compound of Formula 2 followed by intramolecular cyclisation...
Disclosed herein is a process for preparation and purification of DL-Homocysteine thiolactone hydrochloride comprising demethylation of DL-methionine to obtain disodium salt of DL-homocysteine, followed by its cyclisation to obtain DL-Homocysteine thiolactone hydrochloride and removal of inorganic salt from the prod...
The present invention relates to novel impurities of Formula (III) and Formula (IV) of Apremilast and the process for preparation of the same. The present invention further relates to a process of obtaining chemically pure and pharmaceutically acceptable Apremilast of Formula (I), which is free from impurities of Fo...
A process for preparation of 2-ethoxy-1-[[2"-[(hydroxyamino)iminomethyl]-biphenyl-4-yl)]methyl-lH-benzo[d]imidazole-7-carboxylic acid or its inorganic salts, of Formula (I) substantially free of desethyl impurity of Formula (VI) and amide impurity of Formula (VII).
Wherein; R is H, Li, Na, K, Ca, Mg, Ba.
...
The present invention relates to a novel compound of Formula (II), and its use in preparation of Avanafil.
Formula (II)
wherein R is -OH. -CI or -OR1 and R1 is C1 to C3 alkyl group
Disclosed herein is a cost effective process for purification of Promethazine hydrochloride (Figure II) free from its undesired isomer (Figure I) by solvent crystallization.
The present invention discloses novel synthetic processes involving Heck's coupling reaction of 2-substituted thiophene with Heck alkene acceptor such as suitably substituted amide or N-substituted allyl amine or N-methyl acrylamide which is optionally hydrated or acetylated and further subjected to Michael addition...
Disclosed herein is a process for the preparation of high throughput crystalline metformin hydrochloride having uniform panicle size distribution and particle size reduction, with effective removal of impurity, DMA-HC1 using real-time INSITU GRINDING TECHNOLOGY during crystallization process from mother liquor. The ...
The present invention relates to a simple, economic and eco-friendly process for preparation of Azilsartan acid of Formula (I) from compound of Formula (II) by avoiding formation of impurities to great extent, thereby providing highly pure Azilsartan acid of Formula (I).
This invention mainly relates to a process for the purification of rivaroxaban and its pharmaceutically accepted salts, wherein the crude rivaroxaban treated with an acid optionally, in presence of solvent to form clear solution which further precipitates out the pure rivaroxaban or its pharmaceutically accepted sal...
The present invention discloses sustained release vaginal pharmaceutical composition comprising; (a) upto 30% micronized progesterone quick release granules and an effervescent agent; (b) 70% micronized progesterone sustained release granules; and a tablet base along with one or more pharmaceutical excipients.
...
[064] This invention relates to novel intermediate, formula (A) for rivaroxaban and process for the preparation thereof. Further it extends to the process for preparation of rivaroxaban by using the said novel intermediate, by treating with 5-chlorothiophene carbonyl chloride to form the rivaroxaban derivatives of...
[076] The present invention concern towards the prodrug of 5 -chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, rivaroxaban per se; processes for their preparation, and the application in treatment and/or prophylaxis of diseases, especially of thromboembol...
Disclosed herein is a process for the preparation of racemic or optically active compound of 3-[(l,3-benzodioxol-5-yloxy) methyl]-4-(4-fluorophenyl)-l-methylpiperidine by condensing racemic or optically active alkyl sulphonate esters of [4-(4-fluorophenyl)-l-methylpiperidin-3-yl] methanol with alkali metal salt of l...
A novel cost effective process for the synthesis of phosphate salts of l-(9H-carbazol-4yloxy)-3-[[2-(2- methoxyphenoxy) ethyl] amino]-propan-2-ol, (carvedilol phosphate) of formula (II) with high yields and purity is disclosed. More particularly, the invention discloses a process for preparation of crystalline phosp...
A cost effective process for preparation of highly pure diphenhydramine substantially free from impurities is described herein; bromination of diphenyl methane is carried out at 110-115°C. Diphenhydramine HBr salt is isolated in pure form after the condensation. Diphenhydramine is prepared in high purity with the us...
Disclosed herein is a process for the preparation of highly pure Metformin hydrochloride, which is substantially free from melamine and Cyanoguanidine impurities using double crystallization technique.
Disclosed herein are satble pharmaceutical compositions used for treatment and prevention of neuropathy comprising Gabapentin formulated into granules, Alpha lipoic acid formulated into tablet, vitamins such as Methylcobalamin, Folic acid and Pyridoxine formulated into film coated tablet which are filled into hard g...
The present invention discloses a process for preparation of desmethyl diphenyhydramine
hydrochloride (I), in good yield and purity, comprising the steps of; (i)reacting
diphenhydramine carbamate (DPH. carbamate) with a basic compound to form desmethyl
diphenyhydramine base; and (ii)reacting desmethyl diphenyhydr...
Disclosed herein is a novel cost effective process for the production of Cyanocyclohexane which comprises reacting cyclohexanecarboxylicacid chloride with aq. NH3 in the presence of an eutectic mixture (NaCl + H2O) to obtain the cyclohexanecarboxamide; treating cyclohexanecarboxamide with a dehydrating agent to obta...
Synergistic pharmaceutical useful for the treatment of mild & borderline iron deficiency anemia as well as prophylaxis of anemia comprising lower than 100 mg of pharmaceutically acceptable salt of ferrous preferably ferrous ascorbate, vitamin B12 and folic without any effects such as, gastrointestinal irritation, na...
Disclosed herein is crystalline carvedilol phosphate. monohydrate having high
aqueous solubility and the process for preparation tl1ereo The invention further
discloses method for treating hypertension, congestive heart failure and angina in a
mammal, using pharmaceutical compositions comprising the compound o...
Process for isolation of trans tramadol hydrochloride substantially free from cis isomer, comprising acidification of Tramadol base by nitric acid to it"s nitrate salt; isolating and purifying the trans tramadol nitrate by refluxing in methanol; converting the salt to the trans tramadol base by treating with alkali ...
Disclosed herein is a commercially viable process for the production of Ferrous orotate in high yield and purity. Ferrous orotate thus prepared can be employed to fortify foods for the effective treatment of iron-deficiency anemia.
The present invention discloses an improved process for the preparation of (S) clopidogrel or its pharmaceutical salt comprising a step of coupling S-(+) Methyl -amino-(2-chlorophenyl) acetate an intermediate (A) with 2-(2-chloroethyl) thiophene an intermediate (B) in presence of solvent to obtain methyl(2-chlorop...
Disclosed herein is a process for preparation of highly pure Metformin Hydrochloride, wherein said process comprises reacting dimethylamine Hydrochloride prepared insitu with Dicyanodiamide (DCDA) at a temperature ranging 135-140°C for 5-10 hrs to obtain Metformin Hydrochloride substantially free from the impurities...
The present invention discloses a pharmaceutical composition for controlling or reducing the incidence of pregnancy complications in high risk pregnancy comprising folic acid, methylcobalamin and pyridoxine to reduce hyperhomocysteinemia.
Disclosed herein is Sublingual pharmaceutical composition comprising micronized progesterone comprises 90% particles of <5µ & 10% particles are of <10µ., 50% particles are of <3.0µ and 25% particles are of <1.5µ along with pharmaceutically acceptable . excipients, to support developing embryo in progesterone deficie...
The present invention discloses an improved process for production of Methoxsalen wherein the stage of dehydrogenation of dihydroxanthotoxin is carried in presence of sodium acetate as chlorine scavenger to produce Methoxsalen substantially free of impurities of formula A and Formula B.
The present invention relates to a process for purification of Avanafil of Formula (I) through formation of acylated Avanafil of Formula (II).
The present invention discloses a novel process for the manufacture of Gabapentin in high yield through a novel 1-imidine-cyclohexaneaceticacid/ester intermediates of Formula 3 & 8 or iminoether of formula 9 or 10 which on hydrogenation yields Gabapentin. The process also describes the catalytic hydrogenation of cal...
The present invention relates to a novel process for preparation of Mirabegron of Formula (I) using intermediates of Formula (II), (IIIa), (IIIb) and (IV).
The present invention provides a process for the preparation of Daclatasvir dihydrochloride by using novel lH-benzotriazole activated MOC-L-Valine intermediate compound of structural formula IV. The present invention further provides the process for removal of Daclatasvir mono impurity compound of structural formula...
The present invention relates to a process for a green synthesis of (2R)-2-Phenyloxirane Formula 2. (2R) -2-Phenyloxirane Formula 2 is then condensed with an intermediate resulting from reaction of 4-Nitrophenylethylamine Hydrochloride with Benzyl halide. The intermediate resulting from the condensation reaction is ...
The present invention provides an improved, cost effective, solvent free green process for synthesis of highly pure Metformin hydrochloride which is substantially free from impurities i.e. Melamine, Dimethylamine, (4,6-diamino-l,3,5-triazin-2-yl)guanidine and Cyanoguanidine.
The present invention relates to an amorphous co-precipitatesof 5-chloro-N-formyl-N- ({ (5S)-2-oxo-3-[4-(3 -oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thi ophene-2-carboxamide compound of the formula (I) and the process for preparation of the same. The present invention further relates ...
The present invention provides a novel process for the preparation of Teneligliptin and its pharmaceutically acceptable salts thereof. The present invention further provides a novel intermediate e^prnpoundq^ structural formula.... V of Teneligliptin and process for the preparation thereof.
Registered Trademarks
[Class : 5] Dietary And Nutritional Supplements; Dietary, Special Dietary Supplement And Food Supplements Comprised Of Vitamins And/Or Minerals; Health Supplements For Human Consumption; Vitamin Supplements; Probiotic Supplements; Protein Powder For Use As A Nutritional Supplement; Pharmaceutical And Medicinal Preparations; Ayurvedic Preparations, Medicines And Supplement; A...
[Class : 5] Dietary And Nutritional Supplements; Dietary, Special Dietary Supplement And Food Supplements Comprised Of Vitamins And/Or Minerals; Health Supplements For Human Consumption; Vitamin Supplements; Probiotic Supplements; Protein Powder For Use As A Nutritional Supplement; Pharmaceutical And Medicinal Preparations; Ayurvedic Preparations, Medicines And Supplement; A...
[Class : 5] Dietary And Nutritional Supplements; Dietary, Special Dietary Supplement And Food Supplements Comprised Of Vitamins And/Or Minerals; Health Supplements For Human Consumption; Vitamin Supplements; Probiotic Supplements; Protein Powder For Use As A Nutritional Supplement; Pharmaceutical And Medicinal Preparations; Ayurvedic Preparations, Medicines And Supplement; A...
View +313 more Brands for Wanbury Limited.
Charges
30 March 2015
Andhra Bank
7 Crore
07 November 2014
Andhra Bank
47 Lak
22 April 2014
Sbi Global Factors Limited
15 Crore
26 March 2014
Bank Of India
4 Crore
12 October 2011
Bank Of India
14 Crore
29 September 2011
Axis Bank Limited
25 Crore
28 September 2010
Export-import Bank Of India
5 Crore
02 February 2010
Sbicap Trustee Company Limited
528 Crore
29 December 2009
Sbicap Trustee Company Limited
517 Crore
30 November 2009
Export-import Bank Of India
4 Crore
12 August 2009
Andhra Bank
7 Crore
29 July 2009
Edelweiss Asset Reconstruction Company Limited
7 Crore
04 June 2009
Edelweiss Asset Reconstruction Company Limited
11 Crore
04 June 2009
Edelweiss Asset Reconstruction Company Limited
19 Crore
28 March 2009
Idbi Bank Limited
10 Crore
28 March 2009
Andhra Bank
15 Crore
09 March 2009
Axis Bank Limited
24 Crore
19 December 2008
State Bank Of Indore
35 Crore
21 July 2008
Export-import Bank Of India
4 Crore
22 November 2007
Edelweiss Asset Reconstruction Company Limited
37 Crore
03 August 2007
Export-import Bank Of India
3 Crore
08 January 2007
Export-import Bank Of India
4 Crore
13 November 2006
Export-import Bank Of India
30 Crore
26 April 2005
Bank Of India
85 Crore
15 May 1997
Bank Of India
141 Crore
20 March 1997
Bank Of India
10 Crore
04 October 2007
Export- Import Bank Of India
12 Crore
19 July 2023
Sbicap Trustee Company Limited
0
08 January 2007
Others
0
03 August 2007
Others
0
26 April 2005
Bank Of India
0
13 November 2006
Others
0
15 May 1997
Bank Of India
0
30 March 2015
Others
0
07 November 2014
Others
0
28 September 2010
Others
0
29 December 2009
Sbicap Trustee Company Limited
0
02 February 2010
Sbicap Trustee Company Limited
0
30 November 2009
Others
0
12 August 2009
Others
0
28 March 2009
Others
0
21 July 2008
Others
0
04 June 2009
Others
0
28 March 2009
Idbi Bank Limited
0
09 March 2009
Axis Bank Limited
0
22 November 2007
Others
0
04 June 2009
Others
0
29 July 2009
Others
0
29 September 2011
Axis Bank Limited
0
04 October 2007
Export- Import Bank Of India
0
22 April 2014
Sbi Global Factors Limited
0
20 March 1997
Bank Of India
0
19 December 2008
State Bank Of Indore
0
12 October 2011
Bank Of India
0
26 March 2014
Bank Of India
0
19 July 2023
Sbicap Trustee Company Limited
0
08 January 2007
Others
0
03 August 2007
Others
0
26 April 2005
Bank Of India
0
13 November 2006
Others
0
15 May 1997
Bank Of India
0
30 March 2015
Others
0
07 November 2014
Others
0
28 September 2010
Others
0
29 December 2009
Sbicap Trustee Company Limited
0
02 February 2010
Sbicap Trustee Company Limited
0
30 November 2009
Others
0
12 August 2009
Others
0
28 March 2009
Others
0
21 July 2008
Others
0
04 June 2009
Others
0
28 March 2009
Idbi Bank Limited
0
09 March 2009
Axis Bank Limited
0
22 November 2007
Others
0
04 June 2009
Others
0
29 July 2009
Others
0
29 September 2011
Axis Bank Limited
0
04 October 2007
Export- Import Bank Of India
0
22 April 2014
Sbi Global Factors Limited
0
20 March 1997
Bank Of India
0
19 December 2008
State Bank Of Indore
0
12 October 2011
Bank Of India
0
26 March 2014
Bank Of India
0
19 July 2023
Sbicap Trustee Company Limited
0
08 January 2007
Others
0
03 August 2007
Others
0
26 April 2005
Bank Of India
0
13 November 2006
Others
0
15 May 1997
Bank Of India
0
30 March 2015
Others
0
07 November 2014
Others
0
28 September 2010
Others
0
29 December 2009
Sbicap Trustee Company Limited
0
02 February 2010
Sbicap Trustee Company Limited
0
30 November 2009
Others
0
12 August 2009
Others
0
28 March 2009
Others
0
21 July 2008
Others
0
04 June 2009
Others
0
28 March 2009
Idbi Bank Limited
0
09 March 2009
Axis Bank Limited
0
22 November 2007
Others
0
04 June 2009
Others
0
29 July 2009
Others
0
29 September 2011
Axis Bank Limited
0
04 October 2007
Export- Import Bank Of India
0
22 April 2014
Sbi Global Factors Limited
0
20 March 1997
Bank Of India
0
19 December 2008
State Bank Of Indore
0
12 October 2011
Bank Of India
0
26 March 2014
Bank Of India
0
Documents
Form AOC-4(XBRL)-19112020_signed
Optional Attachment-(2)-18112020
List of share holders, debenture holders;-18112020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-18112020
XBRL document in respect Consolidated financial statement-18112020
Copy of MGT-8-18112020
Optional Attachment-(1)-18112020
Form MGT-7-18112020_signed
Form MGT-14-06112020_signed
Optional Attachment-(1)-06112020
Optional Attachment-(2)-06112020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-06112020
Optional Attachment-(3)-06112020
Optional Attachment-(4)-06112020
Form MSME FORM I-28102020_signed
Form DPT-3-26102020-signed
Form MGT-15-15102020_signed
Form ADT-1-13102020_signed
Copy of written consent given by auditor-12102020
Copy of resolution passed by the company-12102020
Form PAS-3-19092020
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-19092020
Copy of Board or Shareholders? resolution-19092020
Form DPT-3-30072020-signed
Form MSME FORM I-20062020_signed
Form DIR-12-27022020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-26022020
Optional Attachment-(1)-26022020
Form PAS-3-24022020_signed
Copy of Board or Shareholders? resolution-24022020
